Director and Illumina Funds Disclose 9.6% Stake in Alamar Biosciences Post-IPO

summarizeSummary

Illumina Innovation Funds and Director Nicholas Naclerio have disclosed a 9.6% beneficial ownership in Alamar Biosciences, Inc. post-IPO, representing a significant stake valued at over $151 million.

check_boxKey Events

• Significant Ownership Disclosure

  Illumina Innovation Fund II, L.P., Illumina Innovation Fund III, L.P., and Director Nicholas Naclerio collectively reported beneficial ownership of 6,363,612 shares, representing 9.6% of Alamar Biosciences' common stock.

• Post-IPO Stake

  This substantial ownership was established following the company's initial public offering, with shares acquired through the conversion of preferred stock and convertible notes, and a direct purchase in the IPO.

• Director Involvement

  Nicholas Naclerio, a director of Alamar Biosciences, Inc., is the sole managing member of the general partners for both Illumina Innovation Funds, linking the significant institutional stake directly to an insider.

• Lock-Up Agreement

  The reporting persons are subject to a 180-day lock-up agreement, restricting the sale or transfer of their shares for that period, which provides near-term stability.

auto_awesomeAnalysis

This initial Schedule 13D filing reveals that Illumina Innovation Funds and Director Nicholas Naclerio collectively hold a substantial 9.6% beneficial ownership in Alamar Biosciences, Inc. following its recent IPO. The significant stake, valued at over $151 million, signals strong conviction from a key pre-IPO investor and an insider. The reporting persons are also subject to a 180-day lock-up agreement, providing near-term stability for the stock. This disclosure comes as the company's stock trades near its 52-week high, reflecting positive market reception post-IPO.